Boothbay Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boothbay Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.7M	Buy	64,733 +30,527	+89%	+$1.67M	0.05%	442
2026 Q1	$1.93M	Buy	+34,206	New	+$1.99M	0.03%	642
2025 Q4	–	Sell	-11,800	Closed	-$639K	–	1990
2025 Q3	$639K	Sell	11,800 -300	-2%	-$17.2K	0.01%	1034
2025 Q2	$665K	Buy	+12,100	New	+$713K	0.01%	814
2023 Q2	–	Sell	-25,781	Closed	-$2.43M	–	1840
2023 Q1	$2.51M	Buy	25,781 +19,019	+281%	+$1.97M	0.05%	564
2022 Q4	$700K	Buy	6,762 +1,941	+40%	+$182K	0.02%	1045
2022 Q3	$409K	Sell	4,821 -7,343	-60%	-$654K	0.01%	1340
2022 Q2	$1.01M	Buy	12,164 +6,034	+98%	+$480K	0.03%	803
2022 Q1	$473K	Sell	6,130 -3,973	-39%	-$332K	0.01%	1326
2021 Q4	$893K	Buy	+10,103	New	+$834K	0.02%	808
2021 Q2	–	Sell	-12,152	Closed	-$918K	–	1855
2021 Q1	$918K	Buy	+12,152	New	+$993K	0.03%	639
2020 Q2	–	Sell	-7,980	Closed	-$793K	–	974
2020 Q1	$674K	Buy	+7,980	New	+$688K	0.06%	394
2017 Q2	–	Sell	-5,575	Closed	-$489K	–	678
2017 Q1	$489K	Buy	+5,575	New	+$496K	0.09%	266

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Boothbay Fund Management's BMRN Position: Q2 2026 in Review

Boothbay Fund Management increased its BioMarin Pharmaceuticals (BMRN) stake by 89% in Q2 2026, buying an estimated $1.67M and bringing the position to 64,733 shares worth $3.7M. The position accounts for 0.05% of the portfolio, ranked #442.

Boothbay Fund Management first reported a position in BMRN in Q1 2017 and has held it in 13 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Boothbay Fund Management held 64,733 shares of BioMarin Pharmaceuticals worth $3.7M as of Q2 2026.
Boothbay Fund Management bought 30,527 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.67M.
BioMarin Pharmaceuticals made up 0.05% of Boothbay Fund Management's portfolio in Q2 2026, its #442 holding.
Boothbay Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.